Tags · Compound
retatrutide
Triple GIP, GLP-1 and glucagon receptor agonist; phase 3 ongoing.
Related in this group: semaglutide · tirzepatide · cagrilintide · cagrisema · liraglutide · dulaglutide · exenatide · orforglipron · oral semaglutide · survodutide · mazdutide · amylin analogues
36 topics · page 2 of 2
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Biased agonism: a real phenomenon, an over-used explanation
Posting this under the heading it deserves: Biased agonism: a real phenomenon, an over-used explanation Everything below is what sits behind that. A documentation question rather than an analytical one. I…
|
+130 | 135 | 23k | 16mo |
|
What we do not know about retatrutide, listed explicitly
The question in the title: What we do not know about retatrutide, listed explicitly I will give what I have already checked below so nobody repeats it. Comparing FLOW ( N Engl J Med , 2024) with SURMOUNT-OSA…
|
+106 | 113 | 4.8k | 17mo |
|
Biased agonism: a real phenomenon, an over-used explanation — what changed since
Biased agonism: a real phenomenon, an over-used explanation — what changed since — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I…
|
+49 | 56 | 47k | 17mo |
|
Glucagon receptor agonism in a weight-loss compound
On the subject in the title: Glucagon receptor agonism in a weight-loss compound Working notes rather than a conclusion. Posting the method first, because I know what the first three replies will otherwise…
|
2 | 5.1k | 20mo | |
|
About the Retatrutide category
Triple GIP/GLP-1/glucagon receptor agonist. Phase 2 data, TRIUMPH programme, and cautious practical discussion. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit…
|
4 | 12k | 2y | |
|
Second pass at: Retatrutide dose escalation in the published trials
Second pass at: Retatrutide dose escalation in the published trials — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim…
|
+115 | 125 | 30k | 2y |